DepressionNCT04982757
Accelerated TMS for Depression and OCD
A study testing MagVenture MagPro System with Brainsight neuronavigation device in people with Depression and OCD, run by Weill Medical College of Cornell University at 1 site in United States.
Trial summary
Repetitive transcranial magnetic stimulation (rTMS) is a FDA-approved treatment for depression and Obsessive Compulsive Disorder (OCD). The goal of the study is to learn how to optimize the treatment to improve symptoms of depression and OCD. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Depression, OCD
- What is being tested?
- MagVenture MagPro System with Brainsight neuronavigation device
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 500 participants
- Where
- 1 siteUnited States
- Study dates
- 7 Dec 2021to Aug 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of major depressive disorder OR obsessive-compulsive disorder (DSM-V criteria)
- Hamilton Depression Rating Scale score greater than or equal to 18 OR Yale-Brown Obsessive-Compulsive Scale score greater than or equal to 16
- Failed at least 1 prior trial of standard first-line treatment for depression or OCD per the modified Antidepressant Treatment History form and APA Practice Guidelines (e.g. serotonin reuptake inhibitor [SRI] or cognitive behavioral therapy with exposure and response prevention) OR had refused these treatments for individual reasons (e.g., cannot tolerate side effects, cannot tolerate exposure therapy, etc.).
- Off antidepressants OR on a stable dose of antidepressants for greater than or equal to four weeks with plans to remain on this stable dose during the study Note: Medications that are known to increase cortical excitability (e.g., buprorion, maprotiline, tricyclic antidepressants, classical antipsychotics) or to have an inhibitory effect on brain excitability (e.g., anticonvulsants, benzodiazepines, and atypical antipsychotics), or any other medications with relative hazard for use in TMS will be allowed upon review of medications and/or motor threshold determination by TMS specialist.
- Capacity to consent
Who cannot join
- Imminent risk of suicide (based on the CSSRS)
- Presence of primary psychiatric diagnoses other than OCD, MDD and/or co-morbid GAD (ex. PTSD, MDD with psychotic features, primary psychotic illness, Bipolar I or II)
- Evidence of cognitive impairment (MMSE score falling 1 SD below mean score for his/her age and education)
- Evidence of psychotic symptoms on diagnostic interview (interfering with capacity to consent)
- Have met criteria for any significant substance use disorder within the past 6 months
- Recent onset (within 8 weeks of screening) of psychotherapy
Show all 13Show fewer
- Prior completion of this accelerated TMS treatment protocol during the current depressive episode
- Participated in any clinical trial with an investigational drug or device within the past 6 weeks prior to screening
- Evidence or history of significant neurological disorder including moderate-severe head trauma, stroke, Parkinson's disease or other movement disorder (except benign essential tremor), epilepsy
- History of seizures (except juvenile febrile seizures) or any condition/concurrent medication that could notably lower seizure threshold
- Presence of foreign metal bodies/implanted intracranial devices (MRI contraindication)
- Current pregnancy or planning to conceive during the study
- Abnormal bloodwork for electrolytes, thyroid or liver function
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Repetitive transcranial magnetic stimulation (rTMS) is a FDA-approved treatment for depression and Obsessive Compulsive Disorder (OCD). The goal of the study is to learn how to optimize the treatment to improve symptoms of depression and OCD. This research project will test a new accelerated 5-day accelerated rTMS protocol for treating symptoms of depression and OCD.
A second goal of this study is to identify biomarkers of depression and OCD in the brain using functional magnetic resonance imaging (fMRI). This approach will predict who will benefit from TMS, determine the optimal treatment target, and improve treatment outcomes. Subjects will receive a clinical assessment of symptoms and an fMRI brain scan before and after each treatment course to measure the effect of treatment on symptom severity and on fMRI measures of functional connectivity.
Read more
Participants will be randomized to receive rTMS targeting either the lateral prefrontal cortex (LPFC) or the dorsomedial prefrontal cortex (DMPFC). Participants will complete a 5-day course of rTMS delivered hourly for 10 hours per day. Participants who show a partial response to treatment but not a full response will then receive a second 5-day course. Treatment non-responders will be crossed over to receive rTMS targeting the opposite brain area.
The primary hypothesis is that accelerated rTMS treatment will yield rapid improvement in symptoms for patients with depression and OCD in just 5 days, and that response rates can be further improved by adding a second 5-day treatment course.
- Conditions
- Depression, OCD
- Being tested
- MagVenture MagPro System with Brainsight neuronavigation device
- Keywords
- TMS
- Medical subject headings
- Depression
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MagVenture MagPro System with Brainsight neuronavigation deviceDevice
10x daily sessions of 1200 pulses of theta-burst stimulation lasting approximately ten minutes.
| Study group | Role | What they receive |
|---|---|---|
| Depression - DMPFC target to (for non-responders) LPFC target | Experimental | Participants with treatment resistant depression will receive a 5-day course of rTMS delivered to the DMPFC. Participants may have the option to be crossed over to receive rTMS targeting the opposite brain area (LPFC), enabling us to test whether participants who do not respond well to one target might respond to stimulation of another target. The option to offer a second course of treatment will be based on clinical judgement and re-evaluation of the participant. Receives: Device: MagVenture MagPro System with Brainsight neuronavigation device |
| Depression - LPFC target to (for non-responders) DMPFC target | Active comparator | Participants with treatment resistant depression will receive a 5-day course of rTMS delivered to the LPFC. Participants may have the option to be crossed over to receive rTMS targeting the opposite brain area (DMPFC), enabling us to test whether participants who do not respond well to one target might respond to stimulation of another target. The option to offer a second course of treatment will be based on clinical judgement and re-evaluation of the participant. Receives: Device: MagVenture MagPro System with Brainsight neuronavigation device |
| OCD - DMPFC target to (for non-responders) LPFC target | Experimental | Participants with OCD will receive a 5-day course of rTMS delivered to the DMPFC.Participants may have the option to be crossed over to receive rTMS targeting the opposite brain area (LPFC), enabling us to test whether participants who do not respond well to one target might respond to stimulation of another target. The option to offer a second course of treatment will be based on clinical judgement and re-evaluation of the participant. Receives: Device: MagVenture MagPro System with Brainsight neuronavigation device |
| OCD - LPFC target to (for non-responders) DMPFC target | Active comparator | Participants with OCD will receive a 5-day course of rTMS delivered to the LPFC. Participants may have the option to be crossed over to receive rTMS targeting the opposite brain area (DMPFC), enabling us to test whether participants who do not respond well to one target might respond to stimulation of another target. The option to offer a second course of treatment will be based on clinical judgement and re-evaluation of the participant. Receives: Device: MagVenture MagPro System with Brainsight neuronavigation device |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent Change in Yale-Brown Obsessive Compulsive Scale (YBOCS) scores for participants with OCD
The YBOCS is a measure of obsessive compulsive symptoms is scored on a scale of 0 to 40, with 0 being no symptoms and 40 being extreme symptoms of OCD.
Measured: Baseline to Treatment End: Day 5, 10, 15, or 20 (depending on number of 5-day treatment courses administered)
Change in Montgomery-Asberg Depression Rating Scale (MADRS) scores for participants with treatment resistant depression
The MADRS is a measure of depression symptoms and is scored on a scale of 0 to 60, with 0 being no depressive symptoms and 60 being severe depressive symptoms.
Measured: Baseline to Treatment End: Day 5 or 10 (depending on number of 5-day treatment courses administered)
Secondary outcomes (10)
Percent Change in Quick Inventory of Depressive Symptomatology (QIDS) scores for participants with OCD
The QIDS is a self-report measure of depression symptoms and is scored on a scale of 0 to 27, with 0 being no depressive symptoms and 27 being severe depressive symptoms.
Measured: Baseline to Treatment End: Day 5 or 10 (depending on number of 5-day treatment courses administered)
Percent Change in Beck Depression Inventory (BDI) scores for participants with OCD
The BDI is a self-report measure of depression symptoms and is scored on a scale of 0 to 63, with 0 being no depressive symptoms and 63 being severe depressive symptoms.
Measured: Baseline to Treatment End: Day 5 or 10 (depending on number of 5-day treatment courses administered)
Percent Change in Patient Health Questionnaire (PHQ-9) scores for participants with OCD
The PHQ-9 is a self-report measure of depression symptoms and is scored on a scale of 0 to 63, with 0 being no depressive symptoms and 63 being severe depressive symptoms.
Measured: Baseline to Treatment End: Day 5 or 10 (depending on number of 5-day treatment courses administered)
Percent Change in Patient Health Questionnaire-9 (PHQ-9) scores for participants with OCD
The PHQ-9 is a self-report measure of depression symptoms and is scored on a scale of 0 to 63, with 0 being no depressive symptoms and 27 being severe depressive symptoms.
Measured: Baseline to Treatment End: Day 5 or 10 (depending on number of 5-day treatment courses administered)
Percent Change in Beck Anxiety Inventory (BAI) scores for participants with OCD
The BAI is a self-report measure of anxiety symptoms and is scored on a scale of 0 to 63, with 0 being no anxiety symptoms and 63 being severe anxiety symptoms.
Measured: Baseline to Treatment End: Day 5 or 10 (depending on number of 5-day treatment courses administered)
Percent Change in General Anxiety Disorder (GAD-7) scores for participants with OCD
The BAI is a self-report measure of anxiety symptoms and is scored on a scale of 0 to 21, with 0 being no anxiety symptoms and 21 being severe anxiety symptoms.
Measured: Baseline to Treatment End: Day 5 or 10 (depending on number of 5-day treatment courses administered)
Percent Change in 17-item Hamilton Depression Rating Scale (HAM-D) scores for participants with treatment resistant depression
The HAM-D is a clinician-rated measure of depression symptoms and is scored on a scale of 0 to 52, with 0 being no anxiety symptoms and 21 being severe depression symptoms.
Measured: Baseline to Treatment End: Day 5 or 10 (depending on number of 5-day treatment courses administered)
Percent Change in Beck Depression Inventory (BDI) scores for participants with treatment resistant depression
The BDI is a self-report measure of depression symptoms and is scored on a scale of 0 to 63, with 0 being no depressive symptoms and 63 being severe depressive symptoms.
Measured: Baseline to Treatment End: Day 5 or 10 (depending on number of 5-day treatment courses administered)
Change in resting-state fMRI connectivity between the frontostriatal network and limbic network in participants with OCD
Change in resting state fMRI connectivity between the frontostriatal network and limbic network will be measured as a between-network correlational score of 0 to 1, with 0 low between-network connectivity and 1 being the highest possible between-network connectivity.
Measured: Baseline to Treatment End: Day 5 or 10 (depending on number of 5-day treatment courses administered)
Change in resting-state fMRI connectivity between the frontostriatal network and limbic network in participants with treatment resistant depression
Change in resting state fMRI connectivity between the frontostriatal network and limbic network will be measured as a between-network correlational score of 0 to 1, with 0 low between-network connectivity and 1 being the highest possible between-network connectivity.
Measured: Baseline to Treatment End: Day 5 or 10 (depending on number of 5-day treatment courses administered)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jul 2021
- Study start7 Dec 2021
- Primary completionMay 2027 (estimated)
- Study completionAug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DepressionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Subjects will be randomized to receive rTMS targeting the DMPFC or the LPFC. The treatment course will be 10 sessions per day hourly for 5 days. Participants may have the option to be crossed over to receive rTMS targeting the opposite brain area, enabling us to test whether participants who do not respond well to one target might respond to stimulation of another target. The option to offer a second course of treatment will be based on clinical judgement and re-evaluation of the participant.
- Masking
- None (open label)
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Weill Medical College of Cornell University
- Sponsor type
- University, hospital or other
- Collaborators
- The New Venture Fund / Foundation for OCD Research, The Wellcome Leap Fund, National Institute of Mental Health (NIMH)
- Responsible party
- Sponsor
- Investigators
- Conor Liston, MD, PhD, Principal investigator, Weill Medical College of Cornell University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04982757
- Sponsor's protocol ID
- 20-10022827
- Other IDs
- UG3MH137656
- Status last verified
- Aug 2026
- First submitted
- 17 Jul 2021
- Last updated
- 20 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Yes: Individual data collected during the trial will be available after deidentification upon request to the PI. Data to be shared include deidentified clinical assessment scores and MRI images.
Study at a glance
From the registry record, last updated by the sponsor on 20 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Accelerated TMS for Depression and OCD
- ClinicalTrials.gov ID
- NCT04982757
- Acronym / sponsor ID
- 20-10022827
- Conditions
- Depression, OCD
- Keywords
- TMS
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Weill Medical College of Cornell UniversityUniversity, hospital or other
- Collaborators
- The New Venture Fund / Foundation for OCD Research, The Wellcome Leap Fund, National Institute of Mental Health (NIMH)
- Study start
- 7 Dec 2021 (actual)
- Primary completion
- May 2027 (estimated)
- Study completion
- Aug 2027 (estimated)
- First posted
- 29 Jul 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Repetitive transcranial magnetic stimulation (rTMS) is a FDA-approved treatment for depression and Obsessive Compulsive Disorder (OCD). The goal of the study is to learn how to optimize the treatment to improve symptoms of depression and OCD. This research project will test a new accelerated 5-day accelerated rTMS protocol for treating symptoms of depression and OCD.
A second goal of this study is to identify biomarkers of depression and OCD in the brain using functional magnetic resonance imaging (fMRI). This approach will predict who will benefit from TMS, determine the optimal treatment target, and improve treatment outcomes. Subjects will receive a clinical assessment of symptoms and an fMRI brain scan before and after each treatment course to measure the effect of treatment on symptom severity and on fMRI measures of functional connectivity.
Participants will be randomized to receive rTMS targeting either the lateral prefrontal cortex (LPFC) or the dorsomedial prefrontal cortex (DMPFC). Participants will complete a 5-day course of rTMS delivered hourly for 10 hours per day. Participants who show a partial response to treatment but not a full response will then receive a second 5-day course. Treatment non-responders will be crossed over to receive rTMS targeting the opposite brain area.
The primary hypothesis is that accelerated rTMS treatment will yield rapid improvement in symptoms for patients with depression and OCD in just 5 days, and that response rates can be further improved by adding a second 5-day treatment course.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 4
- Model description
- Subjects will be randomized to receive rTMS targeting the DMPFC or the LPFC. The treatment course will be 10 sessions per day hourly for 5 days. Participants may have the option to be crossed over to receive rTMS targeting the opposite brain area, enabling us to test whether participants who do not respond well to one target might respond to stimulation of another target. The option to offer a second course of treatment will be based on clinical judgement and re-evaluation of the participant.
| Arm | Type | Receives |
|---|---|---|
| Depression - DMPFC target to (for non-responders) LPFC target | Experimental | Device: MagVenture MagPro System with Brainsight neuronavigation deviceParticipants with treatment resistant depression will receive a 5-day course of rTMS delivered to the DMPFC. Participants may have the option to be crossed over to receive rTMS targeting the opposite brain area (LPFC), enabling us to test whether participants who do not respond well to one target might respond to stimulation of another target. The option to offer a second course of treatment will be based on clinical judgement and re-evaluation of the participant. |
| Depression - LPFC target to (for non-responders) DMPFC target | Active comparator | Device: MagVenture MagPro System with Brainsight neuronavigation deviceParticipants with treatment resistant depression will receive a 5-day course of rTMS delivered to the LPFC. Participants may have the option to be crossed over to receive rTMS targeting the opposite brain area (DMPFC), enabling us to test whether participants who do not respond well to one target might respond to stimulation of another target. The option to offer a second course of treatment will be based on clinical judgement and re-evaluation of the participant. |
| OCD - DMPFC target to (for non-responders) LPFC target | Experimental | Device: MagVenture MagPro System with Brainsight neuronavigation deviceParticipants with OCD will receive a 5-day course of rTMS delivered to the DMPFC.Participants may have the option to be crossed over to receive rTMS targeting the opposite brain area (LPFC), enabling us to test whether participants who do not respond well to one target might respond to stimulation of another target. The option to offer a second course of treatment will be based on clinical judgement and re-evaluation of the participant. |
| OCD - LPFC target to (for non-responders) DMPFC target | Active comparator | Device: MagVenture MagPro System with Brainsight neuronavigation deviceParticipants with OCD will receive a 5-day course of rTMS delivered to the LPFC. Participants may have the option to be crossed over to receive rTMS targeting the opposite brain area (DMPFC), enabling us to test whether participants who do not respond well to one target might respond to stimulation of another target. The option to offer a second course of treatment will be based on clinical judgement and re-evaluation of the participant. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Diagnosis of major depressive disorder OR obsessive-compulsive disorder (DSM-V criteria)
- Hamilton Depression Rating Scale score greater than or equal to 18 OR Yale-Brown Obsessive-Compulsive Scale score greater than or equal to 16
- Failed at least 1 prior trial of standard first-line treatment for depression or OCD per the modified Antidepressant Treatment History form and APA Practice Guidelines (e.g. serotonin reuptake inhibitor [SRI] or cognitive behavioral therapy with exposure and response prevention) OR had refused these treatments for individual reasons (e.g., cannot tolerate side effects, cannot tolerate exposure therapy, etc.).
- Off antidepressants OR on a stable dose of antidepressants for greater than or equal to four weeks with plans to remain on this stable dose during the study Note: Medications that are known to increase cortical excitability (e.g., buprorion, maprotiline, tricyclic antidepressants, classical antipsychotics) or to have an inhibitory effect on brain excitability (e.g., anticonvulsants, benzodiazepines, and atypical antipsychotics), or any other medications with relative hazard for use in TMS will be allowed upon review of medications and/or motor threshold determination by TMS specialist.
- Capacity to consent
Key exclusion criteria (13 listed)
- Imminent risk of suicide (based on the CSSRS)
- Presence of primary psychiatric diagnoses other than OCD, MDD and/or co-morbid GAD (ex. PTSD, MDD with psychotic features, primary psychotic illness, Bipolar I or II)
- Evidence of cognitive impairment (MMSE score falling 1 SD below mean score for his/her age and education)
- Evidence of psychotic symptoms on diagnostic interview (interfering with capacity to consent)
- Have met criteria for any significant substance use disorder within the past 6 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MagVenture MagPro System with Brainsight neuronavigation device10x daily sessions of 1200 pulses of theta-burst stimulation lasting approximately ten minutes. | Device | Depression - DMPFC target to (for non-responders) LPFC target, Depression - LPFC target to (for non-responders) DMPFC target, OCD - DMPFC target to (for non-responders) LPFC target, OCD - LPFC target to (for non-responders) DMPFC target |
Primary outcome
Percent Change in Yale-Brown Obsessive Compulsive Scale (YBOCS) scores for participants with OCD
Time frame: Baseline to Treatment End: Day 5, 10, 15, or 20 (depending on number of 5-day treatment courses administered)
The YBOCS is a measure of obsessive compulsive symptoms is scored on a scale of 0 to 40, with 0 being no symptoms and 40 being extreme symptoms of OCD.
Change in Montgomery-Asberg Depression Rating Scale (MADRS) scores for participants with treatment resistant depression
Time frame: Baseline to Treatment End: Day 5 or 10 (depending on number of 5-day treatment courses administered)
The MADRS is a measure of depression symptoms and is scored on a scale of 0 to 60, with 0 being no depressive symptoms and 60 being severe depressive symptoms.
10 secondary outcomes
Percent Change in Quick Inventory of Depressive Symptomatology (QIDS) scores for participants with OCD
Time frame: Baseline to Treatment End: Day 5 or 10 (depending on number of 5-day treatment courses administered)
Percent Change in Beck Depression Inventory (BDI) scores for participants with OCD
Time frame: Baseline to Treatment End: Day 5 or 10 (depending on number of 5-day treatment courses administered)
Percent Change in Patient Health Questionnaire (PHQ-9) scores for participants with OCD
Time frame: Baseline to Treatment End: Day 5 or 10 (depending on number of 5-day treatment courses administered)
Percent Change in Patient Health Questionnaire-9 (PHQ-9) scores for participants with OCD
Time frame: Baseline to Treatment End: Day 5 or 10 (depending on number of 5-day treatment courses administered)
Percent Change in Beck Anxiety Inventory (BAI) scores for participants with OCD
Time frame: Baseline to Treatment End: Day 5 or 10 (depending on number of 5-day treatment courses administered)
Percent Change in General Anxiety Disorder (GAD-7) scores for participants with OCD
Time frame: Baseline to Treatment End: Day 5 or 10 (depending on number of 5-day treatment courses administered)
Percent Change in 17-item Hamilton Depression Rating Scale (HAM-D) scores for participants with treatment resistant depression
Time frame: Baseline to Treatment End: Day 5 or 10 (depending on number of 5-day treatment courses administered)
Percent Change in Beck Depression Inventory (BDI) scores for participants with treatment resistant depression
Time frame: Baseline to Treatment End: Day 5 or 10 (depending on number of 5-day treatment courses administered)
Change in resting-state fMRI connectivity between the frontostriatal network and limbic network in participants with OCD
Time frame: Baseline to Treatment End: Day 5 or 10 (depending on number of 5-day treatment courses administered)
Change in resting-state fMRI connectivity between the frontostriatal network and limbic network in participants with treatment resistant depression
Time frame: Baseline to Treatment End: Day 5 or 10 (depending on number of 5-day treatment courses administered)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Aug 2026.
- Individual participant dataSharing planned: Yes. Individual data collected during the trial will be available after deidentification upon request to the PI. Data to be shared include deidentified clinical assessment scores and MRI images.
Related trials for Depression
RecruitingPhase 2
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
Anxiety Disorders, Major Depressive Disorder
Recruiting
Virtual Reality Intervention to Improve Psychological Symptom Burden for Cancer Patients Undergoing Treatment
Adjustment Disorder, Anxiety Disorder
Recruiting
Teenthrive 2: Treatments for Improving Mood in Teens
Depression in Adolescence
Active, not recruiting
Developing and Testing an Online Pathway From Screening to Treatment for Depression in Oncology: iPath*D (Aim 2)
Cancer, Depression
RecruitingPhase 2
Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder
Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Conor Liston, MD, PhD principal investigator
Weill Medical College of Cornell University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing MagVenture MagPro System with Brainsight neuronavigation device in people with Depression and OCD, run by Weill Medical College of Cornell University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 20 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percent Change in Yale-Brown Obsessive Compulsive Scale (YBOCS) scores for participants with OCD (time frame: Baseline to Treatment End: Day 5, 10, 15, or 20 (depending on number of 5-day treatment courses administered)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Aug 2026.